Medtech
Fresenius Kabi Launches Single-Needle Option for the Amicus Extracorporeal Photopheresis Protocol
Fresenius Kabi announced the availability of a single-needle venous access option for the Amicus Extracorporeal Photopheresis (ECP) System at the 49th annual…
Fresenius Kabi announced the availability of a single-needle venous access option for the Amicus Extracorporeal Photopheresis (ECP) System at the 49th annual meeting of the European Society for Blood and Marrow Transplantation (EBMT).
AiThority Interview Insights: AiThority Interview with Brad Anderson, President of Product and Engineering at Qualtrics
“We are thrilled to enable the single-needle option for the Amicus Blue ECP system, which will allow physicians to treat patients with limited venous access. This builds on our Amicus Blue vision to provide a versatile, multi-procedural instrument to support patients’ individual needs”
Fresenius Kabi is a global health care company that specializes in medicines and technologies for infusion, transfusion and clinical nutrition.
The Amicus Blue System with online ECP was launched in Europe in 2019 with double-needle venous access only. The update announced today includes new software v6.1 for the Amicus Separator, new software v2.1 for the Phelix Photoactivation Device and a new single-use disposable kit that can be configured for single or double-needle venous access. The system also allows clinicians to switch between single and double-needle access at any time during the procedure.
“We are thrilled to enable the single-needle option for the Amicus Blue ECP system, which will allow physicians to treat patients with limited venous access. This builds on our Amicus Blue vision to provide a versatile, multi-procedural instrument to support patients’ individual needs,” said Christian Hauer, President Fresenius Kabi MedTech.
Read More about AiThority Interview: AiThority Interview with Ajay Sathyanath, Chief Technology Officer at Madison Logic
The Amicus ECP System has obtained CE mark for the indication of CTCL in the palliative treatment of the skin manifestations of cutaneous T-cell lymphoma (CTCL) that is unresponsive to other forms of treatment. The Amicus ECP System is CE marked in compliance with the applicable requirements of the Medical Device Regulation (EU) 2017/745 and includes:
- Amicus Separator
- Phelix Photoactivation Device
- Amicus ECP Apheresis Kits
Amicus Separator is also cleared in Europe and the United States for therapeutic plasma exchange (TPE), red blood cell exchange (RBCx), mononuclear cell (MNC) collection and platelet collection. The Amicus ECP System is not cleared for use in the U.S.
Not all products listed are available or approved for sale in all countries. Contact your local Fresenius Kabi representative for additional information and product availability. Refer to the Amicus Separator Operator’s Manual and Phelix Photoactivation Device Operator’s Manual for a complete list of warnings and precautions associated with the use of these products.
Latest AiThority Interview Insights : AiThority Interview with at Brian Sathianathan, Co-Founder and CTO at Iterate.ai
[To share your insights with us, please write to sghosh@martechseries.com]
The post Fresenius Kabi Launches Single-Needle Option for the Amicus Extracorporeal Photopheresis Protocol appeared first on AiThority.
ETF Talk: AI is ‘Big Generator’
Second nature comes alive Even if you close your eyes We exist through this strange device — Yes, “Big Generator” Artificial intelligence (AI) has…
Apple gets an appeals court win for its Apple Watch
Apple has at least a couple more weeks before it has to worry about another sales ban.
Federal court blocks ban on Apple Watches after Apple appeal
A federal appeals court has temporarily blocked a sweeping import ban on Apple’s latest smartwatches while the patent dispute winds its way through…
